Abstract
Tuberculosis (TB) caused by Mycobacterium tuberculosis claims millions of lives each year globally. Although it can be controlled by currently available drug regimen (DOTS), yet the emergence of multidrug resistance (MDR) and extensively drug resistance (XDR) TB is a growing concern. The increasing rate of MDR-TB, co-infection with HIV and XDR-TB necessitates the development of new anti-TB agents that have a practical impact on tuberculosis control. This review article gives a brief introduction of tuberculosis, present day problems, traditional and new anti-TB drug targets, currently used drugs, their mode of action, the pipeline compounds and a short description of new chemical entities (NCEs) as antitubercular agents developed in last 10 years.
Keywords: Antitubercular agents, Arabinogalactan, Chemotherapy, Extensively Drug Resistance (XDR), Fatty acid synthase, MultiDrug Resistance (MDR), Mycobacterium tuberculosis, Mycolic acid, Peptidoglycan, Tuberculosis (TB)
Current Medicinal Chemistry
Title: Developments in Chemical Approaches to Treat Tuberculosis in the Last Decade
Volume: 19 Issue: 4
Author(s): R. P. Tripathi, S. S. Bisht, A. Ajay, A. Sharma, M. Misra and M. Pd. Gupt
Affiliation:
- Medicinal and Process Chemistry Division, Central Drug Research Institute, M. G. Marg, Lucknow-226001, U.P., India.,India
Keywords: Antitubercular agents, Arabinogalactan, Chemotherapy, Extensively Drug Resistance (XDR), Fatty acid synthase, MultiDrug Resistance (MDR), Mycobacterium tuberculosis, Mycolic acid, Peptidoglycan, Tuberculosis (TB)
Abstract: Tuberculosis (TB) caused by Mycobacterium tuberculosis claims millions of lives each year globally. Although it can be controlled by currently available drug regimen (DOTS), yet the emergence of multidrug resistance (MDR) and extensively drug resistance (XDR) TB is a growing concern. The increasing rate of MDR-TB, co-infection with HIV and XDR-TB necessitates the development of new anti-TB agents that have a practical impact on tuberculosis control. This review article gives a brief introduction of tuberculosis, present day problems, traditional and new anti-TB drug targets, currently used drugs, their mode of action, the pipeline compounds and a short description of new chemical entities (NCEs) as antitubercular agents developed in last 10 years.
Export Options
About this article
Cite this article as:
P. Tripathi R., S. Bisht S., Ajay A., Sharma A., Misra M. and Pd. Gupt M., Developments in Chemical Approaches to Treat Tuberculosis in the Last Decade, Current Medicinal Chemistry 2012; 19(4) . https://dx.doi.org/10.2174/092986712798918815
| DOI https://dx.doi.org/10.2174/092986712798918815 |
Print ISSN 0929-8673 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Allegations from Whistleblowers
- Publishing Ethics
- Increase Visibility Of Your Article
- Self Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
New Anti-Tuberculosis Drugs with Novel Mechanisms of Action
Current Medicinal Chemistry Innate T-Cell Immunity in HIV Infections: The Role of Vg9Vd2 T Lymphocytes
Current Molecular Medicine The Impact of Proteomic Advances on Bacterial Gene Annotation
Current Proteomics Bioinformatics and the Discovery of Novel Anti-Microbial Targets
Current Drug Targets - Infectious Disorders Therapy of XDR TB with Thioridazine a Drug Beyond Patent Protection but Eligible for Patent “As New Use”
Recent Patents on Anti-Infective Drug Discovery Current Status of Some Antituberculosis Drugs and the Development of new Antituberculous Agents with Special Reference to their In Vitro and In Vivo Antimicrobial Activities
Current Pharmaceutical Design Developments on Drug Delivery Systems for the Treatment of Mycobacterial Infections
Current Topics in Medicinal Chemistry In Vitro Anti-mycobacterial Activity of Three Medicinal Plants of Lamiaceae Family
Recent Patents on Anti-Infective Drug Discovery New Insights into Lipidic Secondary Metabolites in Mycobacteria
Current Chemical Biology Nanocarriers for Respiratory Diseases Treatment: Recent Advances and Current Challenges
Current Topics in Medicinal Chemistry Virtual Screening and in vitro Antibacterial Activity for the Identification of Novel Inhibitors of Mycobacterium tuberculosis Methionine Aminopeptidase
Current Enzyme Inhibition Carbonic Anhydrases as Drug Targets - An Overview
Current Topics in Medicinal Chemistry New Tuberculosis Drugs in Development
Current Topics in Medicinal Chemistry Design, Synthesis and Anti-tuberculosis Activity of Hydrazones and N-acylhydrazones Containing Vitamin B6 and Different Heteroaromatic Nucleus
Letters in Drug Design & Discovery The Role of Surrogate Markers in the Clinical Evaluation of Antituberculous Chemotherapy
Current Medicinal Chemistry - Anti-Infective Agents Immunogenicity and Therapeutic Effects of pVAX1-rv1419 DNA from Mycobacterium tuberculosis
Current Gene Therapy Benzothiazol Clubbed Imidazol-4-ones as Anti-fungal, Anti-tubercular and Anti-HIV-1 Agents: Their Synthesis and Molecular Docking Study
Letters in Drug Design & Discovery XDR-TB, What is it; How is it Treated; and why is Therapeutic Failure so High?
Recent Patents on Anti-Infective Drug Discovery Prevalence of Tuberculosis in a Prison in Tehran by Active Case Finding
Infectious Disorders - Drug Targets Biopharmaceutics, Pharmacokinetics and Pharmacodynamics of Antituberculosis Drugs
Current Medicinal Chemistry

